About Iovance Biotherapeutics, Inc. 

Iovance Biotherapeutics, Inc. is the global leader in innovating, developing, and delivering tumor infiltrating lymphocyte (TIL) cell therapies for patients with solid tumors. Amtagvi® (lifileucel) is the first FDA-approved, one-time treatment for previously treated advanced melanoma, now approved in three global markets and available at more than 95 authorized treatment centers. The Iovance TIL platform spans registrational trials and next-generation programs in additional solid tumors, including gene-edited and IL-12 tethered TIL therapies, next-generation IL-2, and precision immuno-oncology approaches. As the first and only company to take TIL therapy from concept to a broadly accessible commercial treatment, Iovance operates as an end-to-end cell therapy company, anchored by fully owned, centralized U.S.-based manufacturing that is scaled to serve thousands of cancer patients worldwide each year. For more information, please visit www.iovance.com.

Amtagvi® and its accompanying design marks, Proleukin®, Iovance®, and IovanceCares™ are trademarks and registered trademarks of Iovance Biotherapeutics, Inc. or its subsidiaries. All other trademarks and registered trademarks are the property of their respective owners.

Information on Iovance’s broad, industry-leading patent portfolio is available on the Intellectual Property page on www.iovance.com.

Overview

Iovance Biotherapeutics aims to be the global leader in innovating, developing and delivering tumour-infiltrating lymphocyte (TIL) therapy for people with cancer. We are pioneering a transformational approach to treating cancer by harnessing the ability of the human immune system to recognise and attack diverse cancer cells in each patient. The company’s first product, AMTAGVI (lifileucel), an autologous T-cell therapy using TIL, was recently approved by the Therapeutic Goods Administration (TGA) and is indicated for the treatment of advanced melanoma. Iovance is preparing to launch this novel treatment in the Australian market.

The Commercial Lead, Australia is the senior commercial leader accountable for establishing, commercialising and scaling Iovance’s business in the Australian market. This role owns the Australian commercial strategy and profit-and-loss performance, including revenue, operating expenses, forecasting, resource allocation and achievement of business objectives for AMTAGVI and Proleukin. The Commercial Lead will direct the full sales cycle—from market development, account planning, referral generation and patient identification through treatment-centre activation, completed patient infusions, revenue generation and ongoing account growth. This individual will report directly to the SVP, Global Access, Operations and Proleukin.

The Commercial Lead will lead the authorisation and commercial activation of AMTAGVI treatment centres and provide operational and quality oversight after authorisation. The individual will build executive and clinical relationships across treatment centres and referral networks; ensure medical, nursing, laboratory, pharmacy, quality and administrative stakeholders are prepared to deliver TIL therapy; and align internal functions to move eligible patients from identification and referral through tumour procurement, manufacturing coordination, treatment scheduling, completed infusion and revenue recognition.

As the senior business leader for Australia, the individual will set the country commercialisation strategy, lead launch and market development, and be accountable for commercial performance in the near term and in preparation for national public access. The role will represent the Australian business in global planning, investment, forecasting and performance discussions and will build the commercial capabilities and organisation required as the market grows.

Essential Functions and Responsibilities

• Own and lead the Australian commercialisation strategy, launch plan and ongoing business performance for AMTAGVI and Proleukin.
• Hold profit-and-loss accountability for the Australian business, including revenue, operating expenses, forecasts, budgets, investments, resource allocation and profitability.
• Establish annual and long-range commercial plans, performance measures and resource priorities aligned with global business objectives.
• Lead the full sales cycle across authorised treatment centres and referral networks, from opportunity identification, account planning and customer education through patient identification, referral, treatment scheduling, completed infusion, revenue generation and ongoing account growth.
• Achieve patient infusion, demand and revenue targets for AMTAGVI and Proleukin while maintaining compliance with applicable laws, regulations and company policies.
• Build and manage the Australian commercial forecast using treatment-centre readiness, referral activity, patient identification, scheduling, manufacturing, infusion and revenue data.
• Develop and maintain executive, clinical and operational relationships with treatment centres, referral sites, health-service leaders, clinicians, Commonwealth and state health authorities, public and private funders, reimbursement stakeholders, hospital decision-makers and other partners required to establish and expand TIL therapy in Australia.
• Lead the TIL treatment-centre authorisation process using risk-based tools for authorisation, training, monitoring and disqualification, and provide ongoing operational and quality oversight of authorised treatment centres.
• Lead operational meetings with medical leadership from medical oncology, surgery and cell therapy to establish a standard-of-care pathway for TIL therapy.
• Lead cross-functional treatment-centre meetings with nursing, laboratory, pharmacy, quality and operational champions to develop product and patient workflows and remove barriers to treatment.
• Develop and execute training for authorised users and ensure access to chain-of-identity and chain-of-custody systems is provided to trained individuals.
• Lead cross-functional execution across Market Access, Treatment Centre Operations, Medical Affairs, Business Analytics, Finance, Human Resources, Legal, Supply Chain, Patient Services and global commercial teams.
• Serve as the senior business representative for Australia in global planning, forecasting, investment and performance reviews.
• Design the future Australian commercial organisation and lead the selection, development and performance of additional team members as the market grows.
• Lead or participate in advisory board meetings to identify market-development and educational needs.
• Adhere to Iovance Biotherapeutics’ core values and business ethics.
• Maintain compliance with corporate policies and procedures and with Australian healthcare laws and regulations.
• Perform other duties reasonably within the scope of the role, as required.

Required Education, Skills, and Knowledge

• A relevant bachelor’s degree or an equivalent combination of education and senior commercial leadership experience; an MBA or other relevant postgraduate qualification is preferred.
• Extensive progressive experience in oncology or biotechnology commercial and customer-facing leadership roles, typically gained through 12 or more years of relevant experience; cell therapy and hospital experience are strongly preferred.
• Demonstrated success leading a pharmaceutical or biotechnology product launch at the country or regional level; solid tumour launch experience is preferred.
• Demonstrated profit-and-loss ownership and delivery against revenue, operating expense, budget and profitability targets.
• Experience leading an end-to-end sales process tied to patient treatment, administration or infusion, including demand generation, patient conversion, completed treatment and revenue recognition.
• Strong forecasting, financial planning, budget management, business analytics and performance-management experience.
• Experience building a market, commercial capability or country organisation with limited existing infrastructure.
• Experience developing and building service lines at public or private teaching hospitals or tertiary hospitals is preferred, with a strong understanding of transplant or cell therapy service lines.
• Experience in, or demonstrated ability to learn, the cellular therapy field, including service-line operations, quality, cell laboratories and nursing. A strong understanding of the environment and influences affecting treatment-centre providers and personnel is critical.
• High clinical aptitude in oncology and immunotherapy, with strong operational and commercial acumen in tertiary hospital and community oncology settings.
• Executive presence and demonstrated ability to influence senior internal and external stakeholders and deliver compelling oral presentations.
• Ability to manage competing priorities, make sound decisions and meet time-sensitive business requirements.
• Ability to lead effectively through influence within a matrix organisation and build organisational capability as the Australian business grows.

Iovance will provide reasonable workplace adjustments during recruitment and employment to enable a suitably qualified person to perform the inherent requirements of the role, unless doing so would cause unjustifiable hardship. Please contact Human Resources to request an adjustment.

Inherent Requirements

• Regular use of standard office technology and participation in virtual and in-person meetings.
• The successful candidate must be based in Australia and have ongoing legal working rights in Australia.
• A current driver licence and the ability to undertake regular domestic travel, anticipated to be up to 75%, are inherent requirements of the role.

Role capabilities: Clear and strategic thinking, sound judgement, problem-solving and analysis; the ability to manage competing priorities, exercise appropriate discretion and meet time-sensitive business requirements.

Work Environment

This role operates in field, remote-office, treatment-centre and other business environments and requires the use of standard office technology.

#li-remote